In recent financial disclosures, Jeanette M. Bjorkquist, the Principal Accounting Officer at Assembly Biosciences, Inc. (NASDAQ:ASMB), reported a stock transaction involving the sale of company shares. The transaction comes as the company’s stock trades near its 52-week low of $9.56, with InvestingPro data showing a significant 39% decline year-to-date. According to the SEC Form 4 filing, Bjorkquist sold 180 shares of Assembly Biosciences common stock, raising approximately $1,772. The shares were sold at a weighted average price of $9.8481, with individual transactions occurring within a price range of $9.56 to $10.40.
The sale, which took place on March 31, 2025, was executed to cover tax withholding obligations related to the vesting of restricted stock units. This transaction was mandated by an administrative rule from the company’s Compensation Committee, rather than being a discretionary move by Bjorkquist. With a market capitalization of approximately $69 million, Assembly Biosciences maintains a "Fair" financial health score according to InvestingPro analysis.
In addition to the sale, Bjorkquist also reported the acquisition of 1,655 shares of common stock on March 29, 2025, as part of a grant of restricted stock units. These units are set to vest in equal installments over the next four years, assuming continuous service. Additionally, Bjorkquist received stock options to purchase 1,900 shares, which will vest over four years, with full vesting by March 29, 2029.
These transactions reflect routine financial activities associated with employee compensation and tax obligations, providing insights into insider activities at Assembly Biosciences. Notably, analyst price targets suggest significant upside potential, with targets ranging from $31 to $36 per share. For deeper insights into Assembly Biosciences’ financial health and growth prospects, including 8 additional ProTips, visit InvestingPro.
In other recent news, Assembly Biosciences has initiated a Phase 1a clinical trial for ABI-6250, an investigational oral therapy for chronic hepatitis delta virus (HDV) infection. The trial aims to evaluate the safety and tolerability of the drug, with results expected in the third quarter of 2025. In another development, the company reported positive interim results from its Phase 1a study of ABI-1179, a drug candidate for recurrent genital herpes. This progress has prompted Assembly Biosciences to advance ABI-1179 into the Phase 1b portion of the study, alongside a similar study for another candidate, ABI-5366. Additionally, Assembly Biosciences has extended its sublease for office and laboratory space in South San Francisco through 2029, securing its operational base in a key biotech hub. The sublease agreement includes escalating rent payments, reflecting a strategic move to maintain its presence in the competitive market. These developments highlight Assembly Biosciences’ ongoing efforts in advancing its pipeline of investigational therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.